Literature DB >> 6141060

The production of asymmetry and circling behaviour following unilateral, intrastriatal administration of neuroleptic agents: a comparison of abilities to antagonise striatal function.

B Costall, M E Kelly, R J Naylor.   

Abstract

The abilities of typical and atypical neuroleptic agents to antagonise at striatal dopamine receptors were determined in the rat. Neuroleptic agents were injected unilaterally into the striatum and asymmetric body posturing/circling behaviour (always ipsilateral to the side of neuroleptic injection) assessed (1) to neuroleptic challenge alone (vehicle injected into the contralateral striatum), (2) as that revealed after neuroleptic challenge by peripherally administered apomorphine or (3) by dopamine injection into the contralateral striatum. Unilateral intrastriatal fluphenazine (1-5 micrograms), cis- and trans-flupenthixol (1-20 micrograms), haloperidol (0.5-5 micrograms), thioridazine (5-10 micrograms), clozapine (1-5 micrograms), tiapride (1-5 micrograms), metoclopramide (1-10 micrograms), (+)-sulpiride (20 micrograms) and piperoxan (10 micrograms) each failed, alone, to cause any postural asymmetry/circling. However, ipsilateral asymmetry was induced by unilateral intrastriatal (-)-sulpiride (1-5 micrograms). In contrast, ipsilateral asymmetry developed when the intrastriatal injection of all neuroleptic agents (excepting (+)-sulpiride and trans-flupenthixol) was followed by peripheral challenge with apomorphine: effective neuroleptic doses were all in the range 0.5-10 micrograms, although (-)-sulpiride was effective at 0.001-0.1 microgram. Active circling was only recorded for (-)-sulpiride and tiapride. The striatal imbalance caused by (-)-sulpiride could be revealed by apomorphine for 24 h, although other intrastriatal neuroleptic responses persisted for 6-8 h. The abilities of all neuroleptic agents to cause striatal imbalance could also be revealed by injecting dopamine into the contralateral striatum (at a dose which alone did not cause any asymmetric motor responding). These intrastriatal injection approaches are forwarded as valuable techniques for determining striatal dopamine antagonist activity in the rodent.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6141060     DOI: 10.1016/0014-2999(83)90531-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  The effects of some polyamines on putative behavioural indices of mesolimbic versus striatal dopaminergic function.

Authors:  S R Hirsch; R Richardson-Andrews; B Costall; M E Kelly; J de Belleroche; R J Naylor
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

2.  Neurochemical and behavioural evidence that dopamine D-2 receptors in striatum couple to the Ni regulatory protein and inhibition of cyclic AMP accumulation.

Authors:  E Kelly; A L Willcocks; S R Nahorski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-06       Impact factor: 3.000

3.  Synergistic blockade of some dopamine-mediated behaviours by (-)-sulpiride and SCH 23390 in the rat.

Authors:  R Dall'Olio; P Roncada; A Vaccheri; O Gandolfi; N Montanaro
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Antistereotypic effects of dopamine D-1 and D-2 antagonists after intrastriatal injection in rats. Pharmacological and regional specificity.

Authors:  J Arnt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-08       Impact factor: 3.000

5.  Modification of dyskinesias following the intrastriatal injection of prostaglandins in the rodent.

Authors:  B Costall; S W Holmes; M E Kelly; R J Naylor
Journal:  Br J Pharmacol       Date:  1985-08       Impact factor: 8.739

Review 6.  Tiapride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in geriatric agitation.

Authors:  J W Steele; D Faulds; E M Sorkin
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

Review 7.  Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome.

Authors:  D H Peters; D Faulds
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.